These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29248988)

  • 21. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
    Radecka A; Loughlin L; Foy M; de Ferraz Guimaraes MV; Sarinic VM; Di Giusti MD; Lesicar M; Straus S; Montero D; Pallos J; Ivanovic J; Raine J
    Drug Saf; 2018 Dec; 41(12):1285-1302. PubMed ID: 30128638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.
    Olsson S; Pal SN; Stergachis A; Couper M
    Drug Saf; 2010 Aug; 33(8):689-703. PubMed ID: 20635827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region: results of a 2015 survey.
    Qato DM
    Int J Pharm Pract; 2018 Jun; 26(3):210-221. PubMed ID: 28737220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacovigilance in China: Evolution and future challenges.
    Song H; Pei X; Liu Z; Shen C; Sun J; Liu Y; Zhou L; Sun F; Xiao X
    Br J Clin Pharmacol; 2023 Feb; 89(2):510-522. PubMed ID: 35165914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa.
    Kiguba R; Olsson S; Waitt C
    Br J Clin Pharmacol; 2023 Feb; 89(2):491-509. PubMed ID: 34937122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Safety Evaluation in China.
    Li L; Yin J
    Curr Allergy Asthma Rep; 2019 Jul; 19(9):39. PubMed ID: 31321555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions.
    Mulchandani R; Kakkar AK
    Int J Risk Saf Med; 2019; 30(1):33-44. PubMed ID: 30175985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role and strategy of ISoP in global pharmacovigilance.
    Olsson S; Harrison-Woolrych M
    Int J Clin Pharm; 2018 Aug; 40(4):740-743. PubMed ID: 30073610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacovigilance in Russia: current state of affairs, challenges, and prospects.
    Gildeeva G; Belostotsky A
    Curr Med Res Opin; 2017 Dec; 33(12):2161-2166. PubMed ID: 28562116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
    Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
    J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency.
    Seabroke S; Wise L; Waller P
    Drug Saf; 2013 Oct; 36(10):1025-32. PubMed ID: 23821159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

  • 40. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.